Literature DB >> 15735742

Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis.

Andrea Mohr1, Ralf Michael Zwacka, Gergely Jarmy, Chirlei Büneker, Hubert Schrezenmeier, Konstanze Döhner, Christian Beltinger, Markus Wiesneth, Klaus-Michael Debatin, Karsten Stahnke.   

Abstract

Regulation of sensitivity or resistance for apoptosis by death receptor ligand systems is a key control mechanism in the hematopoietic system. Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia. Control of homeostasis starts at the level of hematopoietic stem cells (HSC). To this end, we found that CD34+ hematopoietic progenitor cells are constitutively resistant to CD95-mediated apoptosis and cannot be sensitized during short-term culture to death receptor-mediated apoptosis by cytokines. Detailed analysis of the death machinery revealed that CD34+ cells do not express caspase-8a/b, a crucial constituent of the death-inducing signaling complex (DISC) of death receptors. Instead, we found a smaller splice variant termed caspase-8L to be present in HSC. Forced expression of caspase-8L using a recombinant lentiviral vector was able to protect hematopoietic cells from death receptor-induced apoptosis even in the presence of caspase-8a/b. Furthermore, we found that caspase-8L is recruited to the DISC after CD95 triggering, thereby preventing CD95 from connecting to the caspase cascade. These results demonstrate an antiapoptotic function of caspase-8L and suggest a critical role as apoptosis regulator in HSC. Similar to CD34+ HSC, stem cell-derived leukemic blasts from AML(M0) patients only expressed caspase-8L. Additionally we found, caspase-8L expression in several AML and ALL samples. Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34+ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735742     DOI: 10.1038/sj.onc.1208432

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  New basal cell carcinoma susceptibility loci.

Authors:  Simon N Stacey; Hannes Helgason; Sigurjon A Gudjonsson; Gudmar Thorleifsson; Florian Zink; Asgeir Sigurdsson; Birte Kehr; Julius Gudmundsson; Patrick Sulem; Bardur Sigurgeirsson; Kristrun R Benediktsdottir; Kristin Thorisdottir; Rafn Ragnarsson; Victoria Fuentelsaz; Cristina Corredera; Yolanda Gilaberte; Matilde Grasa; Dolores Planelles; Onofre Sanmartin; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Bjørn A Nexø; Anne Tjønneland; Kim Overvad; Jon G Jonasson; Laufey Tryggvadottir; Hrefna Johannsdottir; Anna M Kristinsdottir; Hreinn Stefansson; Gisli Masson; Olafur T Magnusson; Bjarni V Halldorsson; Augustine Kong; Thorunn Rafnar; Unnur Thorsteinsdottir; Ulla Vogel; Rajiv Kumar; Eduardo Nagore; José I Mayordomo; Daniel F Gudbjartsson; Jon H Olafsson; Kari Stefansson
Journal:  Nat Commun       Date:  2015-04-09       Impact factor: 14.919

2.  Alternatively spliced caspase-6B isoform inhibits the activation of caspase-6A.

Authors:  Andrea W Lee; Nathalie Champagne; Xiaojun Wang; Xiao-Dong Su; Cynthia Goodyer; Andrea C Leblanc
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

3.  Harnessing the cell death pathway for targeted cancer treatment.

Authors:  Christina K Speirs; Misun Hwang; Sungjune Kim; Weier Li; Sophia Chang; Vinod Varki; Lauren Mitchell; Stephen Schleicher; Bo Lu
Journal:  Am J Cancer Res       Date:  2010-09-30       Impact factor: 6.166

Review 4.  Caspases and cancer.

Authors:  M Olsson; B Zhivotovsky
Journal:  Cell Death Differ       Date:  2011-04-01       Impact factor: 15.828

5.  Evasion of apoptosis as a cellular stress response in cancer.

Authors:  Simone Fulda
Journal:  Int J Cell Biol       Date:  2010-02-18

6.  Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.

Authors:  Xiaolin Hu; Kankana Bardhan; Amy V Paschall; Dafeng Yang; Jennifer L Waller; Mary Anne Park; Asha Nayak-Kapoor; Thomas A Samuel; Scott I Abrams; Kebin Liu
Journal:  J Biol Chem       Date:  2013-05-15       Impact factor: 5.157

Review 7.  Alternative RNA splicing and cancer.

Authors:  Sali Liu; Chonghui Cheng
Journal:  Wiley Interdiscip Rev RNA       Date:  2013-06-13       Impact factor: 9.957

8.  A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants.

Authors:  A Nahimana; D Aubry; L Lagopoulos; P Greaney; A Attinger; S Demotz; K M Dawson; M Schapira; J Tschopp; M Dupuis; M A Duchosal
Journal:  Blood Cancer J       Date:  2011-12-09       Impact factor: 11.037

9.  Alternative splicing and its impact as a cancer diagnostic marker.

Authors:  Yun-Ji Kim; Heui-Soo Kim
Journal:  Genomics Inform       Date:  2012-06-30

10.  Regulation of cell death in cancer-possible implications for immunotherapy.

Authors:  Simone Fulda
Journal:  Front Oncol       Date:  2013-02-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.